RT Journal Article
T1 Aspirin for Evidence-Based Preeclampsia Prevention trial: influence of compliance on beneficial effect of aspirin in prevention of preterm preeclampsia.
A1 Wright, David
A1 Poon, Liona C
A1 Rolnik, Daniel L
A1 Syngelaki, Argyro
A1 Delgado, Juan Luis
A1 Vojtassakova, Denisa
A1 de Alvarado, Mercedes
A1 Kapeti, Evgenia
A1 Rehal, Anoop
A1 Pazos, Andrea
A1 Carbone, Ilma Floriana
A1 Dutemeyer, Vivien
A1 Plasencia, Walter
A1 Papantoniou, Nikos
A1 Nicolaides, Kypros H
K1 Aspirin for Evidence-Based Preeclampsia Prevention trial
K1 aspirin
K1 compliance
K1 first-trimester screening
K1 mean arterial blood pressure
K1 placental growth factor
K1 prediction
K1 preeclampsia
K1 pregnancy-associated plasma protein A
K1 pyramid of pregnancy care
K1 treatment effect
K1 uterine artery Doppler
AB The Aspirin for Evidence-Based Preeclampsia Prevention trial was a multicenter study in women with singleton pregnancies. Screening was carried out at 11-13 weeks' gestation with an algorithm that combines maternal factors and biomarkers (mean arterial pressure, uterine artery pulsatility index, and maternal serum pregnancy-associated plasma protein A and placental growth factor). Those with an estimated risk for preterm preeclampsia of >1 in 100 were invited to participate in a double-blind trial of aspirin (150 mg/d) vs placebo from 11-14 until 36 weeks' gestation. Preterm preeclampsia with delivery at 1 in 100 were invited to participate in a double-blind trial of aspirin (150 mg/d) vs placebo from 11-14 until 36 weeks' gestation. Preterm preeclampsia with delivery at  We sought to examine the influence of compliance on the beneficial effect of aspirin in prevention of preterm preeclampsia in the Aspirin for Evidence-Based Preeclampsia Prevention trial. This was a secondary analysis of data from the trial. The proportion of prescribed tablets taken was used as an overall measure of compliance. Logistic regression analysis was used to estimate the effect of aspirin on the incidence of preterm preeclampsia according to compliance of  Preterm preeclampsia occurred in 5/555 (0.9%) participants in the aspirin group with compliance ≥90%, in 8/243 (3.3%) of participants in the aspirin group with compliance  The beneficial effect of aspirin in the prevention of preterm preeclampsia appears to depend on compliance.
YR 2017
FD 2017-09-06
LK http://hdl.handle.net/10668/11568
UL http://hdl.handle.net/10668/11568
LA en
DS RISalud
RD Apr 7, 2025